CH683149A5
(en)
*
|
1991-07-22 |
1994-01-31 |
Debio Rech Pharma Sa |
Process for the preparation of microspheres of a biodegradable polymeric material.
|
FR2693905B1
(en)
*
|
1992-07-27 |
1994-09-02 |
Rhone Merieux |
Process for the preparation of microspheres for the sustained release of the hormone LHRH and its analogs, microspheres and formulations obtained.
|
US5981719A
(en)
|
1993-03-09 |
1999-11-09 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US6191105B1
(en)
|
1993-05-10 |
2001-02-20 |
Protein Delivery, Inc. |
Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
|
US5681811A
(en)
*
|
1993-05-10 |
1997-10-28 |
Protein Delivery, Inc. |
Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
|
DE4320201A1
(en)
*
|
1993-06-18 |
1995-01-12 |
Asta Medica Ag |
Use of Cetrorelix and other nona and decapeptides for the manufacture of a medicament for combating AIDS and for growth stimulation
|
US6087324A
(en)
*
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
DE4342092B4
(en)
*
|
1993-12-09 |
2007-01-11 |
Zentaris Gmbh |
Long-acting suspension for injection and method of preparation
|
AU6242096A
(en)
|
1995-06-27 |
1997-01-30 |
Takeda Chemical Industries Ltd. |
Method of producing sustained-release preparation
|
US5931809A
(en)
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
DE19545257A1
(en)
|
1995-11-24 |
1997-06-19 |
Schering Ag |
Process for the production of morphologically uniform microcapsules and microcapsules produced by this process
|
KR0162872B1
(en)
*
|
1996-04-01 |
1998-12-01 |
김은영 |
Improved preparation method for biodegradable polymeric microspheres using solvent extraction and preparation method for microspheres for treating local inflammation using the same
|
US20020111603A1
(en)
*
|
1996-12-02 |
2002-08-15 |
Societe De Conseils De Recherches Et D'application |
Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
|
WO1998032423A1
(en)
*
|
1997-01-29 |
1998-07-30 |
Takeda Chemical Industries, Ltd. |
Sustained-release microspheres, their production and use
|
TW577759B
(en)
*
|
1997-04-18 |
2004-03-01 |
Ipsen Pharma Biotech |
Sustained release compositions in the form of microcapsules or implants and the process for their preparation
|
WO1999047543A2
(en)
*
|
1998-03-18 |
1999-09-23 |
University Technology Corporation |
Sustained-release composition including amorphous polymer
|
US6613358B2
(en)
|
1998-03-18 |
2003-09-02 |
Theodore W. Randolph |
Sustained-release composition including amorphous polymer
|
SE9801288D0
(en)
*
|
1998-04-14 |
1998-04-14 |
Astra Ab |
Vaccine delivery system and method of production
|
EP1240896A3
(en)
*
|
1998-07-23 |
2003-03-26 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Encapsulation of water soluble peptides
|
US6270700B1
(en)
|
1998-07-23 |
2001-08-07 |
Societe De Conseils De Recherches Et D'applications Scientifiques, Sas |
Encapsulation of water soluble peptides
|
WO2000004916A1
(en)
*
|
1998-07-23 |
2000-02-03 |
Societe De Conseils De Recherches Et D'applications Scientifiques Sas |
Encapsulation of water soluble peptides
|
US20070009605A1
(en)
*
|
1998-07-23 |
2007-01-11 |
Ignatious Francis X |
Encapsulation of water soluble peptides
|
US6703381B1
(en)
|
1998-08-14 |
2004-03-09 |
Nobex Corporation |
Methods for delivery therapeutic compounds across the blood-brain barrier
|
GB2344519B
(en)
*
|
1998-12-07 |
2004-05-19 |
Johnson & Johnson Medical Ltd |
Sterile therapeutic compositions
|
IT1304152B1
(en)
*
|
1998-12-10 |
2001-03-08 |
Mediolanum Farmaceutici Srl |
COMPOSITIONS INCLUDING A PEPTIDE AND POLYLACTIC-GLYCOLIC ACID FOR THE PREPARATION OF SUBCUTANEOUS IMPLANTS HAVING A PROLONGED
|
US6682724B2
(en)
|
1999-02-23 |
2004-01-27 |
Arch Chemcials, Inc. |
Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
|
US6204308B1
(en)
|
1999-03-01 |
2001-03-20 |
Novartis Ag |
Organic compounds
|
US6317623B1
(en)
*
|
1999-03-12 |
2001-11-13 |
Medrad, Inc. |
Apparatus and method for controlling contrast enhanced imaging procedures
|
JP2002539172A
(en)
|
1999-03-17 |
2002-11-19 |
ノバルティス アクチエンゲゼルシャフト |
Pharmaceutical composition containing TGF-beta
|
EP1044683A1
(en)
*
|
1999-04-15 |
2000-10-18 |
Debio Recherche Pharmaceutique S.A. |
One-step dispersion method for the microencapsulation of water soluble substances
|
ES2169980B1
(en)
*
|
1999-12-17 |
2003-11-01 |
Lipotec Sa |
MICROCAPSULES FOR THE PROLONGED RELEASE OF PHARMACOS.
|
US6309454B1
(en)
|
2000-05-12 |
2001-10-30 |
Johnson & Johnson Medical Limited |
Freeze-dried composite materials and processes for the production thereof
|
WO2002049620A2
(en)
|
2000-12-21 |
2002-06-27 |
Inhale Therapeutic Systems, Inc. |
Induced phase transition method for the production of microparticles containing hydrophobic active agents
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
JP2005504090A
(en)
*
|
2001-09-26 |
2005-02-10 |
バクスター・インターナショナル・インコーポレイテッド |
Preparation of submicron size-nanoparticles by removal of dispersion and solvent or liquid phase
|
US7112340B2
(en)
*
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
KR100885070B1
(en)
*
|
2002-05-08 |
2009-02-25 |
재단법인서울대학교산학협력재단 |
Oligopeptide which binds specifically to PLGA
|
US7655618B2
(en)
*
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
WO2004060387A1
(en)
*
|
2002-12-27 |
2004-07-22 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
SI2246360T1
(en)
|
2003-01-28 |
2012-10-30 |
Ironwood Pharmaceuticals Inc |
Compositions for the treatment of gastrointestinal disorders
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
US20100143485A1
(en)
*
|
2003-03-05 |
2010-06-10 |
Hudnut Paul S |
Oxycontin controlled release formulations and methods of using same
|
US6987111B2
(en)
*
|
2003-08-06 |
2006-01-17 |
Alkermes Controlled Therapeutics, Ii |
Aripiprazole, olanzapine and haloperidol pamoate salts
|
CN105820160B
(en)
|
2003-11-05 |
2019-02-12 |
萨可德生物科学公司 |
Modulators of cellular adhesion
|
US7605123B2
(en)
|
2004-07-19 |
2009-10-20 |
Biocon Ltd. |
Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof
|
PT1781264E
(en)
|
2004-08-04 |
2013-10-16 |
Evonik Corp |
Methods for manufacturing delivery devices and devices thereof
|
ES2255426B1
(en)
*
|
2004-10-19 |
2007-08-16 |
Gp Pharm, S.A. |
PHARMACEUTICAL FORMULATION THAT INCLUDES MICROCAPSULES OF STATINS SUSPENDED IN ESTER ALKYLS OF POLYINSATURATED FATTY ACIDS (PUFA).
|
EP1674082A1
(en)
*
|
2004-12-22 |
2006-06-28 |
Zentaris GmbH |
Process for the manufacture of sterile suspensions or lyophilisates of low-soluble basic peptide complexes, pharmaceutical formulations comprising these complexes and their use as medicament
|
US7608612B2
(en)
*
|
2005-01-21 |
2009-10-27 |
Richard H. Matthews |
Radiosensitizer formulations and methods for use
|
MX2007013213A
(en)
*
|
2005-04-25 |
2007-12-12 |
Amgen Inc |
Biodegradable peptide sustained release compositions containing porogens.
|
JP5794721B2
(en)
|
2005-05-17 |
2015-10-14 |
サーコード バイオサイエンス インコーポレイテッド |
Compositions and methods for the treatment of ocular disorders
|
BRPI0612071A2
(en)
*
|
2005-06-14 |
2010-10-19 |
Baxter Int |
pharmaceutical formulations to minimize drug interactions
|
CN101309669A
(en)
*
|
2005-11-15 |
2008-11-19 |
巴克斯特国际公司 |
Compositions of lipoxygenase inhibitors
|
KR20130024987A
(en)
*
|
2005-12-22 |
2013-03-08 |
노파르티스 아게 |
Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
|
US9301792B2
(en)
*
|
2006-01-27 |
2016-04-05 |
Stryker Corporation |
Low pressure delivery system and method for delivering a solid and liquid mixture into a target site for medical treatment
|
KR100722607B1
(en)
*
|
2006-05-11 |
2007-05-28 |
주식회사 펩트론 |
A process of preparing microspheres for sustained release having improved dispersibility and syringeability
|
US7403325B2
(en)
*
|
2006-05-19 |
2008-07-22 |
Xerox Corporation |
Electrophoretic display device
|
US20080293695A1
(en)
*
|
2007-05-22 |
2008-11-27 |
David William Bristol |
Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
|
US7718649B1
(en)
|
2006-11-10 |
2010-05-18 |
Pisgah Labs, Inc. |
Physical states of a pharmaceutical drug substance
|
US8211905B1
(en)
|
2007-05-22 |
2012-07-03 |
Pisgah Laboratories, Inc. |
Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
|
US7858663B1
(en)
|
2007-10-31 |
2010-12-28 |
Pisgah Laboratories, Inc. |
Physical and chemical properties of thyroid hormone organic acid addition salts
|
US8039461B1
(en)
|
2006-11-10 |
2011-10-18 |
Pisgah Laboratories, Inc. |
Physical states of a pharmaceutical drug substance
|
US20080293814A1
(en)
*
|
2007-05-22 |
2008-11-27 |
Deepak Tiwari |
Concentrate esmolol
|
US10183001B1
(en)
|
2007-05-22 |
2019-01-22 |
Pisgah Laboratories, Inc. |
Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
|
US8722736B2
(en)
*
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
US9421266B2
(en)
|
2007-05-22 |
2016-08-23 |
Pisgah Laboratories, Inc. |
Safety of pseudoephedrine drug products
|
US8329720B1
(en)
|
2007-05-22 |
2012-12-11 |
Pisgah Laboratories, Inc. |
Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties
|
US8426467B2
(en)
*
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
JP5546451B2
(en)
|
2007-06-04 |
2014-07-09 |
シナジー ファーマシューティカルズ インコーポレイテッド |
Agonyl cyclase agonists useful in the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
LT2164467T
(en)
*
|
2007-06-06 |
2017-01-25 |
Debiopharm Research & Manufacturing Sa |
Slow release pharmaceutical composition made of microparticles
|
JP5868594B2
(en)
|
2007-10-16 |
2016-02-24 |
バイオコン・リミテッドBiocon Limited |
Orally administrable solid pharmaceutical composition and process thereof
|
ES2830024T3
(en)
|
2007-10-19 |
2021-06-02 |
Novartis Ag |
Compositions and methods for the treatment of macular edema
|
CA2709712C
(en)
|
2007-12-20 |
2016-05-10 |
Surmodics Pharmaceuticals, Inc. |
Process for preparing microparticles having a low residual solvent volume
|
US8883863B1
(en)
|
2008-04-03 |
2014-11-11 |
Pisgah Laboratories, Inc. |
Safety of psuedoephedrine drug products
|
US8080562B2
(en)
|
2008-04-15 |
2011-12-20 |
Sarcode Bioscience Inc. |
Crystalline pharmaceutical and methods of preparation and use thereof
|
US20090258069A1
(en)
*
|
2008-04-15 |
2009-10-15 |
John Burnier |
Delivery of LFA-1 antagonists to the gastrointestinal system
|
AU2009256157B2
(en)
|
2008-06-04 |
2014-12-18 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
WO2010009319A2
(en)
|
2008-07-16 |
2010-01-21 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
US20100062057A1
(en)
*
|
2008-09-10 |
2010-03-11 |
Pronova BioPharma Norge AS. |
Formulation
|
US11395811B2
(en)
|
2009-03-09 |
2022-07-26 |
Pronova Biopharma Norge As |
Compositions comprising a fatty acid oil mixture comprising EPA and DHA in free acid form and a surfactant, and methods and uses thereof
|
US8378105B2
(en)
*
|
2009-10-21 |
2013-02-19 |
Sarcode Bioscience Inc. |
Crystalline pharmaceutical and methods of preparation and use thereof
|
ES2363965B1
(en)
|
2009-11-20 |
2013-01-24 |
Gp Pharm S.A. |
CAPSULES OF BETABLOCKING ACTIVE PRINCIPLES AND ESTERS OF POLYINSATURATED FATTY ACIDS.
|
ES2363964B1
(en)
|
2009-11-20 |
2012-08-22 |
Gp Pharm, S.A. |
CAPSULES OF PHARMACEUTICAL ACTIVE PRINCIPLES AND ESTERS OF POLYINSATURATED FATTY ACIDS.
|
ES2364011B1
(en)
|
2009-11-20 |
2013-01-24 |
Gp Pharm, S.A. |
CAPSULES OF PHARMACEUTICAL ACTIVE AND ESTERS OF POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES.
|
EP2517697B1
(en)
|
2009-12-23 |
2015-01-07 |
Sigma-Tau Industrie Farmaceutiche Riunite SpA |
Combination composition useful for treating cardiovascular diseases
|
ES2385240B1
(en)
|
2010-07-26 |
2013-09-23 |
Gp-Pharm, S.A. |
CAPSULES OF ACTIVE PHARMACEUTICAL PRINCIPLES AND POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF PROSTATE DISEASES.
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
EP2705013B1
(en)
|
2011-05-04 |
2016-03-30 |
Balance Therapeutics, Inc. |
Pentylenetetrazole derivatives
|
WO2013072767A1
(en)
|
2011-11-18 |
2013-05-23 |
Pronova Biopharma Norge As |
Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
|
US9585896B2
(en)
|
2012-04-04 |
2017-03-07 |
Pronova Biopharma Norge As |
Compositions comprising omega-3 fatty acids and vitamin D for psoriasis, and methods and uses thereof
|
US20150079164A1
(en)
|
2012-04-04 |
2015-03-19 |
Pronova Biopharma Norge As |
Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
|
RU2695522C2
(en)
*
|
2012-05-14 |
2019-07-23 |
Тейдзин Лимитед |
Sterile composition
|
WO2014018748A1
(en)
|
2012-07-25 |
2014-01-30 |
Sarcode Bioscience Inc. |
Lfa-1 inhibitor and polymorph thereof
|
WO2014131024A2
(en)
|
2013-02-25 |
2014-08-28 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
ES2748562T3
(en)
|
2013-02-28 |
2020-03-17 |
Basf As |
A composition comprising a lipid compound, a triglyceride and a surfactant, and methods of using the same
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
CN106061494A
(en)
|
2013-10-10 |
2016-10-26 |
辛纳吉制药公司 |
Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
|
US20160151511A1
(en)
|
2014-12-02 |
2016-06-02 |
Antriabio, Inc. |
Proteins and protein conjugates with increased hydrophobicity
|
CN115025079A
(en)
|
2015-04-28 |
2022-09-09 |
普罗诺瓦生物医药挪威公司 |
Use of structurally enhanced sulfur-containing fatty acids for the prevention and/or treatment of non-alcoholic steatohepatitis
|
EP3402804A1
(en)
|
2016-01-11 |
2018-11-21 |
Synergy Pharmaceuticals Inc. |
Formulations and methods for treating ulcerative colitis
|
WO2019066649A1
(en)
|
2017-09-26 |
2019-04-04 |
Nanomi B.V. |
Method for preparing micro-particles by double emulsion technique
|
IL275002B2
(en)
|
2017-12-06 |
2024-04-01 |
Basf As |
Fatty acid derivatives for treating non-alcoholic steatohepatitis
|